A Meta-analysis About Advanced Pancreatic Cancer: Gemcitabine-based Combination Chemotherapy Vs Gemcitabine Alone

Objective： To investigate Gemcitabine-based combination chemotherapy vsGemcitabine alone in patients with inoperable pancreatic cancer through meta analysis.Methods: MEDLINE and EMBASE searches were supplemented by information fromtrial registers. The choice of treatment group controlled Gemcitabine-based combinationchemotherapy, and Gemcitabine alone in inoperable pancreatice cancer.The primarymeta-analysis was based on1year`s survival rate,6months`PFS, objective remission rateand toxicity. Results:The meta-analysis included9randomized controlled trial. There wasa significant improvement for Gemcitabine-based combination chemotherapy group in6months`PFS, objective remission rate and toxicity. And there was a marginal significantimprovement for Gemcitabine-based combination chemotherapy group in1year`ssurvival rate.Conclusion:Gemcitabine-based combination chemotherapy improved in6months`PFS, objective remission rate in inoperable pancreatic cancer, but more toxicitythan Gemcitabine alone.It should advocate the differences with individual treatment planin clinical practical treatment.